New hope pill aims to stop Leukemia's return after transplant
NCT ID NCT06575296
Summary
This study is testing a new oral drug called revumenib to see if it can safely help prevent certain aggressive types of leukemia from coming back after a patient has received a stem cell transplant. The trial will enroll about 27 patients, including children as young as 2, who have specific genetic changes in their leukemia. The main goal is to find the safest and most effective dose to give as a long-term maintenance therapy for up to two years after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.